Ovarian cancer is a malignant disease that affects women’s ovaries. According to the American Cancer Society, ovarian cancer is the fifth most common cause of cancer-related deaths among women in the United States.
There is still no cure for ovarian cancer, but the good news is that there are ways to reduce your risk of developing this disease. One of these ways is taking aspirin. In this article, we explore the link between aspirin and ovarian cancer prevention.
What is aspirin?
Aspirin is a medication that is used to relieve pain and inflammation. It belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs).
Aspirin works by blocking the production of prostaglandins, which are chemicals that are released in response to injury or inflammation. Prostaglandins cause pain, fever, and inflammation. By blocking their production, aspirin can reduce pain, fever, and inflammation.
How does aspirin reduce the risk of ovarian cancer?
There is mounting evidence that suggests that aspirin can reduce the risk of developing ovarian cancer. The exact mechanism by which aspirin reduces the risk of ovarian cancer is not yet clear, but there are several possible explanations.
One possible explanation is that aspirin reduces the production of prostaglandins, which can promote the growth of cancer cells. Another possible explanation is that aspirin can reduce inflammation in the body, which can also contribute to the growth and spread of cancer cells.
What does research say about aspirin and ovarian cancer prevention?
There have been several studies that have investigated the link between aspirin and ovarian cancer prevention.
A meta-analysis of 12 studies published in the Journal of the National Cancer Institute in 2014 found that regular aspirin use was associated with a reduced risk of ovarian cancer. The study found that women who took aspirin regularly had a 20% lower risk of developing ovarian cancer compared to women who did not take aspirin.
Another study published in the Journal of the National Cancer Institute in 2017 found that regular aspirin use was associated with a 10% lower risk of developing ovarian cancer.
The study analyzed data from over 200,000 women and found that women who took aspirin regularly had a lower risk of developing ovarian cancer compared to women who did not take aspirin.
However, it’s worth noting that not all studies have found a link between aspirin use and ovarian cancer prevention. A study published in the British Journal of Cancer in 2015 found no evidence that aspirin reduced the risk of ovarian cancer.
The study analyzed data from over 300,000 women and found no significant association between aspirin use and ovarian cancer risk.
What are the risks associated with aspirin use?
While aspirin is generally regarded as safe when taken as directed, there are some risks associated with its use.
These risks include stomach ulcers, bleeding in the stomach or intestines, and an increased risk of bleeding, particularly if you are taking other medications that also thin the blood.
Who should take aspirin for ovarian cancer prevention?
The decision to take aspirin for ovarian cancer prevention should be made in consultation with a doctor. Aspirin is not suitable for everyone, and it’s important to weigh the risks and benefits of aspirin use before taking it.
Some people, such as those with a history of stomach ulcers or bleeding disorders, may not be able to take aspirin. Others may need to take a lower dose or take aspirin with food to reduce the risk of stomach ulcers.
Conclusion
Aspirin has been shown to reduce the risk of ovarian cancer, but more research is needed to fully understand the link between aspirin use and ovarian cancer prevention.
If you are considering taking aspirin for ovarian cancer prevention, it’s important to speak with a doctor to determine whether it’s appropriate for you. In the meantime, there are other lifestyle changes you can make to reduce your risk of developing ovarian cancer, including maintaining a healthy weight, eating a healthy diet, and not smoking.